Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025

Core Insights - Madrigal Pharmaceuticals is presenting new data on Rezdiffra (resmetirom) for treating metabolic dysfunction-associated steatohepatitis (MASH) at the upcoming AASLD Liver Meeting, highlighting its potential for advanced patients with compensated cirrhosis [1][2][4] Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for MASH, a liver disease with significant unmet medical needs [19] - Rezdiffra is the first approved medication for MASH in the U.S. and Europe, targeting key underlying causes of the disease [6][19] Clinical Data and Presentations - The company will present two oral presentations and multiple posters at the AASLD meeting, including data on biomarkers, imaging, and quality of life improvements in patients treated with Rezdiffra [4][5] - Key presentations include: - "Two-Year Time Course of Biomarker and Imaging Responses in Well-Compensated MASH Cirrhosis Patients Treated with Resmetirom" [5] - "Improvement in Health-Related Quality of Life in Non-Cirrhotic and Cirrhotic Patients with MASH Treated with Resmetirom" [5] Treatment Efficacy - In the pivotal Phase 3 MAESTRO-NASH trial, Rezdiffra demonstrated significant improvements in fibrosis and MASH resolution, with 91% of patients showing improvement or stabilization of liver stiffness after one year [6][19] - The ongoing Phase 3 MAESTRO-NASH-OUTCOMES trial is evaluating Rezdiffra's efficacy in patients with compensated MASH cirrhosis [2][19] Disease Context - MASH is a serious liver disease that can progress to cirrhosis and liver failure, with increasing prevalence leading to a higher number of diagnosed patients [8][10] - Patients with moderate to advanced fibrosis face significantly higher risks of liver-related mortality, emphasizing the need for effective treatments [9]